- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03456856
A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.
Open-label, Single-arm, Study Assessing the Efficacy and Safety of Ivabradine (Corlanor) in African-American/Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction
This study is a prospective, open-label, single-arm intervention study in African-American/Black subjects with heart failure and reduced ejection fraction (HFrEF).
There will be a 7-day screening period, a 57-day open-label treatment period, and a safety follow-up at day 87 or 30 days after the last administration of the investigational product.
Study Overview
Detailed Description
The goal of this study is to determine the impact of adding ivabradine therapy to the standard of care (SOC) in African-American/Black subjects with Heart Failure (HF) and reduced ejection fraction (HFrEF) on changes in heart rate (HR) from baseline (SOC alone). Changes in HR from baseline will be correlated with the changes from baseline in activity level of the subjects, as measured by both a standard 6-minute walk distance and an accelerometer device.
The primary hypothesis is that ivabradine effectively reduces HR between baseline and day 57 in African-American/Black subjects. Because mean reductions of approximately 5 beat per minute (bpm) have been observed in the overall placebo-treated subjects in the SHIFT study as well as in the placebo-treated subjects of the subgroup analysis of non-African-American/Black subjects enrolled in the SHIFT study, we will test whether the mean reduction with ivabradine exceeds 5 bpm, and estimate the degree to which the mean reduction with ivabradine exceeds 5 bpm.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Delaware
-
Wilmington, Delaware, United States, 19803
- Research Site
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Research Site
-
-
New York
-
Buffalo, New York, United States, 14215
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject has provided informed consent/assent prior to initiation of any study specific activities/ procedures
- Male or female subject ≥ 18 years of age, describing self as African American/Black
- Must have a diagnosis of heart failure (HF) confirmed by medical records, be in stable condition, and treated with stable optimal pharmacological therapy as per their personal physician's care.
- Left ventricular ejection fraction (LVEF) ≤ 35% confirmed by investigator
- New York Heart Association (NYHA) class II to IV assessed at the time of screening
- Electrocardiogram (ECG) documentation at the time of screening of sinus rhythm with resting heart rate (HR) ≥ 70 bpm by local ECG reading
- Must be able to complete a 6-minute walk test (6MWT) and wear an accelerometer
Exclusion Criteria:
- Recent myocardial infarction (≤ 2 months) or stroke (≤ 1 month) prior to enrollment
- If the subject received within 3 months before or is scheduled to receive within 42 days after enrollment any of the following: revascularization, ventricular assist device, continuous or intermittent inotropic therapy, hospice care, major organ transplant, or is receiving renal replacement therapy by dialysis
- If the subject received implantation of a cardioverter defibrillator or cardiac resynchronization therapy within 42 days before or is scheduled to receive implantation of a cardioverter defibrillator or cardiac resynchronization therapy within 42 days after enrollment
- Severe primary valve disease or scheduled for surgery for valvular heart disease
- Pacemaker with atrial or ventricular pacing (except bi-ventricular pacing) >40% of the time, or with a stimulation threshold at the atrial or ventricular level ≥ 60 bpm
- Permanent atrial fibrillation or flutter
- Sick sinus syndrome, sinoatrial block, or second and third degree atrio-ventricular block
- History of symptomatic or sustained (≥ 30 sec) ventricular arrhythmia unless a cardioverter defibrillator was implanted
- History of congenital QT syndrome
- Any cardioverter defibrillator shock experienced within 1 month of enrollment
- Hypertrophic obstructive cardiomyopathy, active myocarditis or constrictive pericarditis, or clinically significant congenital heart disease
- Chronic antiarrhythmic therapy (except digitalis)
- Scheduled outpatient intravenous (IV) infusions for HF (eg, inotropes,vasodilators [eg, nesiritide], diuretics) or routinely scheduled ultrafiltration
- Evidence of digitalis intoxication within 7 days prior to screening
- Systolic blood pressure > 180 mm Hg or < 90 mm Hg, or diastolic blood pressure > 110 mm Hg or < 50 mm Hg at any time during the screening phase
- Known untreated hypothyroidism or hyperthyroidism, adrenal insufficiency, active vasculitis due to collagen vascular disease
- Have known acute or serious co-morbid condition (e.g, major infection or hematologic, renal, hepatic, metabolic, gastrointestinal or endocrine dysfunction) that may interfere with the study, or severe concomitant non-cardiovascular disease that is expected to reduce life expectancy to less than 1 year or malignancy within 5 years prior to enrollment with the following exceptions: localized basal or squamous cell carcinoma of the skin or cervical intraepithelial neoplasia
- Subjects taking QT prolonging medicinal products for cardiovascular (e.g, but not limited to, quinidine, disopyramide, bepridil, sotalol, ibutilide, amiodarone) or non-cardiovascular disease (e.g, but not limited to, pimozide, ziprasidone, sertindole, mefloquine, halofantrine, pentamidine, cisapride, IV erythromycin).
- Subjects exposed to a strong CYP3A4 inhibitor (examples of strong CYP3A4 inhibitors include; azole antifungals [eg, itraconazole], macrolide antibiotics [e.g, clarithromycin, telithromycin], human immunodeficiency virus (HIV) protease inhibitors, [eg, nelfinavir], and nefazodone]) within 14 days prior to enrollment, or to a strong CYP3A4 inducer (examples of CYP3A4 inducers include; St. John's wort, rifampicin, barbiturates, and phenytoin) within 28 days prior to enrollment
- Subjects who received diltiazem or verapamil within 48 hours prior to enrollment.
- Previously received ivabradine prior to participation in this study
- Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.
- Female subject is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 14 days after the last dose of investigational product. Females of childbearing potential should only be included in the study after a confirmed menstrual period and a negative highly sensitive urine pregnancy test.
- Female subjects of childbearing potential unwilling to use 1 highly effective method of contraception during treatment and for an additional 14 days after the last dose of investigational product.
- Subject has known sensitivity to any of the products or components to be administered during dosing.
- Subject likely not to be available to complete all protocol required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and investigator's knowledge.
- History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Ivabradine
The starting dose of ivabradine was 5 mg twice daily (BID), although investigators had the discretion to start participants at 2.5 mg BID if participant had a history of conduction defects, or bradycardia that could lead to hemodynamic compromise.
Dose was adjusted at Day 15 (and at any other clinical visit) between 2.5 - 7.5 mg BID based on heart rate and signs/symptoms of bradycardia.
|
Film-coated tablets taken orally with food twice a day.
Tablets supplied in strengths of 5.0 mg and 7.5 mg.
5.0 tablets were split into equal halves for dosages of 2.5 mg.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Heart Rate (HR) at Day 57
Time Frame: Day1 (baseline), Day 57
|
Summary is based on observed data, and no imputation is used for missing values. Least-square mean is from the repeated measures model which includes scheduled visits and baseline HR measurement as covariates. The mean change from baseline in heart rate is compared to -5 beats/min which is observed in the placebo group in the Systolic Heart Failure Treatment with the IF Inhibitor Ivabradine Trial (SHIFT) study ( NCT02441218, PMID 20801500). |
Day1 (baseline), Day 57
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20160231
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure (HF)
-
Aventusoft, LLC.National Heart, Lung, and Blood Institute (NHLBI); Cleveland Clinic FloridaRecruitingHeart Failure (HF)United States
-
Centro Cardiologico MonzinoFederico II University; Fondazione Toscana Gabriele Monasterio; The Mediterranean...RecruitingHF - Heart FailureItaly
-
BayerCompletedHeart Failure (HF)Spain, Italy, Austria, Bulgaria, Greece, Israel, Poland, Portugal, Hungary
-
GE HealthcareQuintiles, Inc.; H2O Clinical LLCCompleted
-
Hasselt UniversityZiekenhuis Oost-LimburgCompletedHeart Failure (HF)Belgium
-
Novartis PharmaceuticalsNo longer availableHeart Failure With Reduced Ejection Fraction (HF-rEF)Germany, Spain, France, Greece, Lebanon, Austria, Ireland, Slovenia, Australia, Philippines, Brazil, Panama, United States, Croatia, Cyprus, Malta, Switzerland, United Arab Emirates
-
Biotronik SE & Co. KGTerminatedAtrial Fibrillation | Heart Failure (HF)France, Czech Republic, Germany, Netherlands, Belgium, Sweden, United Kingdom
-
GE HealthcareQuintiles, Inc.; H2O Clinical LLCCompletedVentricular Dysfunction, Left | Heart Failure (HF)United States
-
Novartis PharmaceuticalsCompletedHeart Failure With Reduced Ejection Fraction (HF-rEF)Japan
Clinical Trials on Ivabradine
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
Asan Medical CenterInstitut de Recherches Internationales ServierCompletedHealthy IndividualKorea, Republic of
-
University of California, San DiegoAmgenCompletedPostural Orthostatic Tachycardia SyndromeUnited States
-
Institut de Recherches Internationales ServierCompleted
-
Institut de Recherches Internationales ServierCompletedCoronary Disease | Ventricular Dysfunction, LeftUnited Kingdom
-
Medical University of WarsawUnknown
-
Qian gengRecruiting
-
Institut de Recherches Internationales ServierCompletedHeart Failure, CongestiveItaly
-
Tel-Aviv Sourasky Medical CenterUnknownPostural Tachycardia Syndrome
-
Kanecia Obie ZimmermanRecruitingLong COVID | Long Covid19 | Long Covid-19United States